Hims & Hers Health Inc. (NYSE:HIMS) CEO Andrew Dudum defended the telehealth company as it navigates a U.S. Federal Trade Commission lawsuit concerning data privacy and advertising practices.
Speaking during a CNBC interview, the executive argued that regulators fundamentally misunderstand how his firm is modernizing the medical landscape.
• Hims & Hers Health stock is charging ahead with explosive momentum. Why is HIMS stock surging?
In July, the FTC launched a major lawsuit against Hims & Hers, claiming the company unlawfully shared sensitive customer health information with online advertisers and utilized deceptive billing tactics.
The FTC claimed sensitive medical data was improperly funneled to digital advertising firms, specifically highlighting Meta Platforms Inc. (NASDAQ:META) and Snap Inc. (NYSE:SNAP).
